Clinical Trials
45 trialsNCT00600496 2026-05-27
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Completed
NCT06012435 2026-05-27
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
Seagen Inc.
Phase 3 Active not recruiting
NCT06780098 2026-05-26
MK-3475-01I
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT06635824 2026-05-05
Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)
Genmab
Phase 3 Active not recruiting
NCT05132075 2026-04-21
KontRASt-02
Novartis
Phase 3 Active not recruiting
NCT05450692 2026-04-16
LATIFY
AstraZeneca
Phase 3 Active not recruiting
NCT01630733 2026-04-15
ENSPIRIT
Achieve Life Sciences
Phase 3 Completed
NCT05633667 2026-03-17
VELOCITY-Lung
Gilead Sciences
Phase 2 Recruiting
NCT06881784 2026-03-12
RASolve 301
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT06228326 2025-10-24
KYANITE-1
Krystal Biotech, Inc.
Phase 1/2 Recruiting
NCT00532155 2025-09-10
VITAL
Sanofi
Phase 3 Completed
NCT04364620 2025-04-06
AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
Alethia Biotherapeutics
Phase 2 Completed
NCT02922764 2025-03-26
A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer
Inspirna, Inc.
Phase 1 Completed
NCT01828112 2025-02-07
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib
Novartis
Phase 3 Completed
NCT04863248 2023-04-14
PRESERVE 4
G1 Therapeutics, Inc.
Phase 2 Terminated
NCT02393248 2023-01-06
Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)
Incyte Corporation
Phase 1/2 Terminated
NCT00103389 2022-06-27
Docetaxel With or Without PI-88 in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Cellxpert Biotechnology Corp.
Phase 2 Completed
NCT01207011 2022-04-12
Amrubicin (AMR) Trial in Patients With Non-small Cell Lung Cancer
Sumitomo Pharma Co., Ltd.
Phase 3 Completed
NCT00054184 2020-10-05
Polyglutamate Paclitaxel Compared With Docetaxel in Treating Patients With Progressive Non-Small Cell Lung Cancer
CTI BioPharma
Phase 3 Terminated
NCT01168973 2019-09-25
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based Chemotherapy
Eli Lilly and Company
Phase 3 Completed
NCT01646125 2019-07-24
An Open-label, Randomized Phase II Study to Evaluate the Efficacy of AUY922 vs Pemetrexed or Docetaxel in NSCLC Patients With EGFR Mutations
Novartis
Phase 2 Terminated
NCT00086268 2017-09-13
ZPACT
Novartis
Phase 3 Completed
NCT01138163 2017-04-19
Study of Bavituximab Plus Docetaxel in Patients With Locally Advanced or Metastatic Non-Squamous Non Small-Cell Lung Cancer
Peregrine Pharmaceuticals
Phase 2 Completed
NCT00312377 2016-09-30
ZODIAC
Sanofi
Phase 3 Completed
NCT00405951 2016-07-21
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS)in Combination With Docetaxel for the Treatment of Non-Small Cell Lung Cancer
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Completed
NCT00766246 2016-04-19
Phase II Avastin Trial for Stage IIIB/IV NSCLC
Pharmatech
Phase 2 Terminated
NCT01348126 2015-11-05
GALAXY
Synta Pharmaceuticals Corp.
Phase 2/3 Terminated
NCT01038752 2015-05-21
Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer
Optimum Therapeutics, LLC
Phase 2 Terminated
NCT00539968 2015-02-05
A Study to Evaluate the Safety, Tolerability, and Activity of Lonafarnib and Docetaxel (Study P04467AM1)(TERMINATED)
Merck Sharp & Dohme LLC
Phase 1/2 Terminated
NCT00511576 2015-01-08
Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors
Mirati Therapeutics Inc.
Phase 1 Terminated
NCT01266512 2014-07-16
C-CRISP
Sanofi
Phase 2 Completed
NCT01362400 2014-05-19
A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Infinity Pharmaceuticals, Inc.
Phase 2 Completed
NCT01038661 2014-02-28
TFINE
Sanofi
Phase 3 Completed
NCT01604863 2012-11-01
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Phase 1 Suspended
NCT00354562 2011-01-07
A Phase 2 Study Evaluating ABT-751 in Combination With Taxotere in Advanced Non-Small Cell Lung Cancer
Abbott
Phase 1/2 Terminated
NCT00826852 2010-07-27
Weekly Docetaxel and Four Weekly Carboplatin in Non-small Cell Lung Cancer Carbo-Tax
Sanofi
Phase 2 Completed
NCT00174772 2010-02-17
Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00174629 2009-12-07
GILT Docetaxel - Non-Small Cell Lung Cancer
Sanofi
Phase 3 Completed
NCT00258739 2009-12-07
Docetaxel in Non Small Cell Lung Cancer (NSCLC)
Sanofi
Phase 2 Completed
NCT00070629 2009-02-10
CPG 7909 Injection in Non-Small Cell Lung Cancer
Pfizer
Phase 2 Completed
NCT00712504 2008-11-11
Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer
Pfizer
Phase 1 Completed
NCT00080080 2007-06-08
Study of Talabostat and Docetaxel in Advanced Non-Small Cell Lung Cancer
Point Therapeutics
Phase 2 Completed
NCT00243204 2007-06-08
Study of Talabostat + Docetaxel Versus Docetaxel in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
Point Therapeutics
Phase 3 Terminated
NCT00066885 2007-05-07
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
Novacea
Phase 1/2 Completed
NCT00073385 2005-08-30
Comparative Trial of Pivanex and Docetaxel Vs Docetaxel Monotherapy in Patients With Advanced Non-Small Cell Lung Cancer
Titan Pharmaceuticals
Phase 2 Completed